Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta‐analysis of individual participant data

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Hepatology

• Publication date

  2014-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hep.26767PMID 24114809
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.

  2013influential reference
• The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis

  2013influential reference
• 315 I148M PNPLA3 POLYMORPHISM IS ASSOCIATED WITH CLINICAL FEATURES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

  2012cited by this paper
• Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro.

  2012cited by this paper
• The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls

  2012cited by this paper
• Feasibility and performance of the FibroScan XL probe

  2012cited by this paper
• Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis.

  2012cited by this paper
• PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals.

  2012cited by this paper
• 712 PNPLA 3 RS738409 GG HOMOZYGOTE STATUS IS ASSOCIATED WITH INCREASED RISK OF HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS

  2012cited by this paper
• Hepatitis C virus and alcohol: same mitotic targets but different signaling pathways.

  2011cited by this paper
• Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease.

  2011cited by this paper
• The PNPLA3 rs738409 148M/M Genotype Is a Risk Factor for Liver Cancer in Alcoholic Cirrhosis but Shows No or Weak Association in Hepatitis C Cirrhosis

  2011cited by this paper
• Genome-Wide Association Analysis of Soluble ICAM-1 Concentration Reveals Novel Associations at the NFKBIK, PNPLA3, RELA, and SH2B3 Loci

  2011cited by this paper
• Need for a three‐focused approach to nonalcoholic fatty liver disease

  2011cited by this paper
• PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence

  2011cited by this paper
• Patatin‐Like phospholipase domain‐containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C

  2011cited by this paper
• 602 PNPLA3 RS734809 C/G POLYMORPHISM IN LIVER CIRRHOSIS: RELATIONSHIP WITH THE ETIOLOGY OF LIVER DISEASE AND HCC OCCURRENCE

  2011cited by this paper
• Hepatocellular carcinoma.

  2011cited by this paper
• Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

  2011cited by this paper
• Impact of patatin‐like phospholipase‐3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C

  2011cited by this paper
• Patatin‐like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma

  2011cited by this paper
• Variant in PNPLA3 is associated with alcoholic liver disease

  2010cited by this paper
• Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease

  2010cited by this paper
• Meta-analysis of individual participant data: rationale, conduct, and reporting

  2010influential reference
• Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians

  2010cited by this paper
• Patatin‐like phospholipase domain containing 3: A case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease

  2010cited by this paper
• Adipokines in liver diseases

  2009cited by this paper
• How should we use information about HWE in the meta-analyses of genetic association studies?

  2008cited by this paper
• Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta‐Analysis

  2008cited by this paper
• Assessment of cumulative evidence on genetic associations: interim guidelines.

  2008cited by this paper
• Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

  2008cited by this paper
• Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

  2007cited by this paper
• The choice of a genetic model in the meta-analysis of molecular association studies.

  2005cited by this paper
• A method for meta‐analysis of molecular association studies

  2005cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Commentary: meta-analysis of individual participants' data in genetic epidemiology.

  2002cited by this paper
• Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

  2001cited by this paper
• Publication bias in meta-analysis: its causes and consequences.

  2000cited by this paper
• Operating characteristics of a rank correlation test for publication bias.

  1994cited by this paper
• An introduction to meta-analysis.

  1989cited by this paper
• Hepatocellular carcinoma.

  1986influential reference
• Meta-analysis in clinical trials.

  1986cited by this paper
• The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods.

  1985cited by this paper
• Conditional logit analysis of qualitative choice behavior

  1972cited by this paper
• Fitting autoregressive models for prediction

  1969cited by this paper

• Germline mutations and somatic mosaicism in steatotic liver diseases and related liver carcinogenesis.

  2026cites this paper
• Potential association between PNPLA3 rs738409 and hepatocellular carcinoma in Egyptian patients with type 2 diabetes mellitus

  2026cites this paper
• Human genetics of metabolic dysfunction–associated steatotic liver disease: from variants to cause to precision treatment

  2025cites this paper
• The Distribution and Survival Association of Genetic Polymorphisms in Thai Patients with Hepatocellular Carcinoma According to Underlying Liver Disease

  2025cites this paper
• Fifteen Years of PNPLA3: Transforming Hepatology Through Human Genetics

  2025cites this paper
• Genetic and non-genetic drivers of histological progression and regression in MASLD.

  2025cites this paper
• Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical application

  2025cites this paper
• PNPLA3 I148M and Hepatocellular Carcinoma

  2025cites this paper
• AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials.

  2025cites this paper
• The impact of the PNPLA3 rs738406 C>G polymorphism on hepatocellular carcinoma risk in Brazilian patients with chronic hepatitis C and advanced fibrosis

  2025cites this paper
• PNPLA3 polymorphism worsens chemotherapy associated liver injury and affects overall survival in colorectal cancer patients with liver metastasis undergoing hepatic resection

  2025cites this paper
• GWAS Study Identifies 3-SNP Risk Variants of PNPLA3/SAMM50 Linked to HCC Development in Individuals with Non-viral Liver Diseases

  2025cites this paper
• Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver Disease

  2025cites this paper
• Clustering-based identification of immune-related gene signatures in hepatocellular carcinoma

  2025cites this paper
• Naringin and Naringenin in Liver Health: A Review of Molecular and Epigenetic Mechanisms and Emerging Therapeutic Strategies

  2025cites this paper
• PNPLA3 I148 M genetic variant in autoimmune hepatitis characterises advanced disease at diagnosis and reduced survival free of cirrhotic events and liver-related mortality

  2024cites this paper
• Population-enriched innate immune variants may identify candidate gene targets at the intersection of cancer and cardio-metabolic disease

  2024cites this paper
• High serum gamma‐glutamyltransferase level after hepatitis C virus elimination is a risk factor for the development of hepatocellular carcinoma

  2024cites this paper
• Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort.

  2024cites this paper
• Global Epidemiological Impact of PNPLA3 I148M on Liver Disease

  2024cites this paper
• Metabolic Syndrome Traits Increase the Risk of Major Adverse Liver Outcomes in Type 2 Diabetes

  2024cites this paper
• An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillance.

  2024cites this paper
• Integrating PNPLA3 into clinical risk prediction

  2024cites this paper
• Decoding 17-Beta-hydroxysteroid Dehydrogenase 13: A Multifaceted Perspective on Its Role in Hepatic Steatosis and Associated Disorders

  2024cites this paper
• Integrating genetic and socioeconomic data to predict the progression of nonalcoholic fatty liver disease

  2024cites this paper
• PNPLA3 in Alcohol‐Related Liver Disease

  2024cites this paper
• Deciphering the multifaceted role of microRNAs in hepatocellular carcinoma: Integrating literature review and bioinformatics analysis for therapeutic insights

  2024cites this paper
• Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA

  2023cites this paper
• Metabolic liver cancer: associations of rare and common germline variants in one-carbon metabolism and DNA methylation genes.

  2023cites this paper
• Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis

  2023cites this paper
• Association of PNPLA3 (rs738409) & TM6SF2 (rs58542926) and ATG16L1 (rs2241880) genetic variants with susceptibility to hepatocellular carcinoma in a group of Egyptian patients with HCV-induced liver cirrhosis

  2023cites this paper
• Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver Disease

  2023cites this paper
• Microbiome and Genetic Factors in the Pathogenesis of Liver Diseases

  2023cites this paper
• Progression to cirrhosis is similar among all ages in nonalcoholic fatty liver disease, but liver-related events increase with age

  2023cites this paper
• Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score

  2023cites this paper
• PNPLA3 allele frequency has no impact on biliary bile acid composition or disease course in patients with primary sclerosing cholangitis

  2022cites this paper
• Molecular mechanisms of liver carcinogenesis related to metabolic syndrome

  2022cites this paper
• Low Frequency of Cancer-Predisposition Gene Mutations in Liver Transplant Candidates with Hepatocellular Carcinoma

  2022cites this paper
• The Pnpla3 Variant I148M Reveals Protective Effects Towards Hepatocellular Carcinoma in Mice via Restoration of Omega-3 Polyunsaturated Fats.

  2022cites this paper
• miR-516a-3P, a potential circulating biomarker in hepatocellular carcinoma, correlated with rs738409 polymorphism in PNPLA3.

  2022cites this paper
• Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges

  2022cites this paper
• Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: Role of metabolic derangement and host genetic variants

  2022cites this paper
• The Role of Chronic Liver Diseases in the Emergence and Recurrence of Hepatocellular Carcinoma: An Omics Perspective

  2022cites this paper
• Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep’s Clothing?

  2022cites this paper
• HSD17B13 and other liver fat-modulating genes predict development of hepatocellular carcinoma among HCV-positive cirrhotics with and without viral clearance after DAA treatment

  2022cites this paper
• Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives

  2021cites this paper
• Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study.

  2021cites this paper
• A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.

  2021cites this paper
• Genetics Is of the Essence to Face NAFLD

  2021cites this paper
• Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD).

  2021cites this paper
• The impact of polymorphism in PNPLA3 and TM6SF2 genes on the susceptibility and survival of hepatitis C-related hepatocellular carcinoma

  2021cites this paper
• Liver specific, systemic and genetic contributors to alcohol-related liver disease progression

  2021cites this paper
• Genetic risk scores and personalization of care in fatty liver disease.

  2021cites this paper
• Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC

  2021cites this paper
• Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.

  2021cites this paper
• Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives

  2021cites this paper
• Mechanisms and disease consequences of nonalcoholic fatty liver disease.

  2021cites this paper
• Update on cardiovascular risk in nonalcoholic fatty liver disease

  2021influential citation
• Increasing prevalence of NAFLD/NASH among children, adolescents and young adults from 1990 to 2017: a population-based observational study

  2021cites this paper
• Pleiotropy within gene variants associated with nonalcoholic fatty liver disease and traits of the hematopoietic system

  2021cites this paper
• The Endless Sources of Hepatocellular Carcinoma Heterogeneity

  2021cites this paper
• Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets

  2021cites this paper
• Genetic and Environmental Susceptibility to Alcoholic Hepatitis.

  2021cites this paper
• Modifiers of liver-related manifestation in the course of NAFLD.

  2020cites this paper
• PNPLA3 rs738409 is not associated with the risk of hepatocellular carcinoma and persistent infection of hepatitis B virus (HBV) in HBV-related subjects: a case-control study and meta-analysis on Asians.

  2020cites this paper
• A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank.

  2020cites this paper
• Liver Disease, Nonalcoholic Fatty

  2020cites this paper
• Established and emerging factors affecting the progression of nonalcoholic fatty liver disease.

  2020cites this paper
• Towards genetic prediction of non-alcoholic fatty liver disease trajectories: PNPLA3 and beyond.

  2020cites this paper
• The landscape of gene mutations in cirrhosis and hepatocellular carcinoma.

  2020cites this paper
• A comprehensive evaluation of single nucleotide polymorphisms associated with hepatocellular carcinoma risk in Asian populations: A systematic review and network meta-analysis.

  2020cites this paper
• Advances in molecular classification and precision oncology in hepatocellular carcinoma.

  2020cites this paper
• Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH

  2020cites this paper
• Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers

  2020cites this paper
• Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease

  2020cites this paper
• Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma

  2020cites this paper
• Genetics of alcohol-related hepatocellular carcinoma - its role in risk prediction

  2020cites this paper
• Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination

  2020cites this paper
• Hepatic Fat—Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs

  2020influential citation
• The effect of PNPLA3 polymorphism as gain in function mutation in the pathogenesis of non-alcoholic fatty liver disease

  2020cites this paper
• Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients

  2020cites this paper
• Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?

  2020influential citation
• Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease.

  2020cites this paper
• Liver fibrogenesis: UN update on established and emerging basic concepts.

  2020cites this paper
• Sofosbuvir and daclatasvir are safe and effective in treatment of recurrent hepatitis C virus in Egyptian patients underwent living donor liver transplantation

  2020cites this paper
• Genetic Aspects of Non-Alcoholic Fatty Liver Disease

  2019cites this paper
• Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH

  2019cites this paper
• American Ancestry Is a Risk Factor for Suspected Nonalcoholic Fatty Liver Disease in Hispanic/Latino Adults.

  2019cites this paper
• The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives

  2019cites this paper
• Enfermedad hepática por alcohol. Guías de práctica clínica. Documento de consenso auspiciado por la AEEH

  2019cites this paper
• PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.

  2019cites this paper
• Hepatocellular carcinoma in the setting of alcohol-related liver disease.

  2019cites this paper
• PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age

  2019cites this paper
• Molecular prognosis in liver cirrhosis

  2019cites this paper
• Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH).

  2019cites this paper
• The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes

  2019cites this paper
• NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment

  2019influential citation
• PNPLA3—A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease

  2019cites this paper
• The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieu

  2019cites this paper
• [Alcoholic liver disease: the roles of genetic-epigenetic factors and the effect of abstinence].

  2019cites this paper